{
    "nctId": "NCT00082433",
    "briefTitle": "Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer",
    "officialTitle": "A Phase III Study of Novel Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane",
    "overallStatus": "COMPLETED",
    "conditions": "Cancer, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1221,
    "primaryOutcomeMeasure": "Overall Survival (OS)",
    "eligibilityCriteria": "* Patients must have received prior treatment which included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).\n* Patients must have received no more than two prior chemotherapy regimens. Patients who have not received treatment for metastatic disease must have relapsed within one year.\n* Patients may not have any history of brain and/or leptomeningeal metastases.\n* Patients may not have Grade 2 or worse neuropathy at the time of study entry.\n* Patients may not have had prior treatment with any epothilones and/or capecitabine (i.e. Xeloda)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}